 |
 |

Transducible Peptide Therapy for Uveal Melanoma and Retinoblastoma
J. William Harbour, MD;
Lori Worley, BS;
Duanduan Ma, PhD;
Michael Cohen, BS
Arch Ophthalmol. 2002;120:1341-1346.
Objective To determine whether transducible peptides that inhibit the oncoproteins
HDM2 and Bcl-2 may selectively kill uveal melanoma and retinoblastoma cells.
Methods Peptides were tested by viability assay, flow cytometry, TUNEL (terminal
deoxynucleotidyl transferasemediated fluorescein-dUTP nick-end labeling)
assay, Western blot analysis, and reverse transcriptionpolymerase chain
reaction in cultured eye tumor cells and normal cells. Preclinical studies
were performed in a rabbit xenograft model of retinoblastoma.
Main Outcome Measures Cell survival, apoptosis, gene expression, and tumor regression.
Results The antiBcl-2 peptide induced apoptosis in tumor cells, but it
also caused apoptosis in normal cells in culture and induced retinal damage
after intravitreal injection. In contrast, the anti-HDM2 peptide induced rapid
accumulation of p53, activation of apoptotic genes, preferential killing of
tumor cells, and minimal retinal damage after intravitreal injection. The
anti-HDM2 peptide also induced regression of human retinoblastoma cells in
rabbit eyes.
Conclusions Peptide transduction is a promising new approach to molecular eye cancer
therapy. Inhibition of HDM2 can selectively activate p53 in transformed cells
and may be an effective strategy for inducing apoptosis in eye cancer cells
with minimal damage to normal ocular tissues.
Clinical Relevance Molecular characteristics of uveal melanoma and retinoblastoma may be
used to design novel therapeutic agents that have greater specificity and
fewer adverse effects than current therapies.
From the Department of Ophthalmology and Visual Sciences and the Division
of Molecular Oncology, Washington University, St Louis, Mo.
CiteULike Connotea Del.icio.us Digg Reddit Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Single-cell imaging of retinal ganglion cell apoptosis with a cell-penetrating, activatable peptide probe in an in vivo glaucoma model
Barnett et al.
Proc. Natl. Acad. Sci. USA 2009;106:9391-9396.
ABSTRACT
| FULL TEXT
The Penetratin Sequence in the Anticancer PNC-28 Peptide Causes Tumor Cell Necrosis Rather Than Apoptosis of Human Pancreatic Cancer Cells
Bowne et al.
Ann. Surg. Oncol. 2008;15:3588-3600.
ABSTRACT
| FULL TEXT
Inhibition of Mitogen-Elicited Signal Transduction and Growth in Prostate Cancer with a Small Peptide Derived from the Functional Domain of DOC-2/DAB2 Delivered by a Unique Vehicle.
Zhou et al.
Cancer Res. 2006;66:8954-8958.
ABSTRACT
| FULL TEXT
Small Molecule Inhibition of HDM2 Leads to p53-Mediated Cell Death in Retinoblastoma Cells.
Elison et al.
Arch Ophthalmol 2006;124:1269-1275.
ABSTRACT
| FULL TEXT
Selective cell uptake of modified tat Peptide-fluorophore conjugates in rat retina in ex vivo and in vivo models.
Barnett et al.
IOVS 2006;47:2589-2595.
ABSTRACT
| FULL TEXT
Eye Cancer: Unique Insights into Oncogenesis The Cogan Lecture
Harbour
IOVS 2006;47:1737-1745.
FULL TEXT
DDEF1 Is Located in an Amplified Region of Chromosome 8q and Is Overexpressed in Uveal Melanoma
Ehlers et al.
Clin. Cancer Res. 2005;11:3609-3613.
ABSTRACT
| FULL TEXT
Functional Analysis of the p53 Pathway in Response to Ionizing Radiation in Uveal Melanoma
Sun et al.
IOVS 2005;46:1561-1564.
ABSTRACT
| FULL TEXT
MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A
Loercher et al.
JCB 2005;168:35-40.
ABSTRACT
| FULL TEXT
Gene Expression Profiling in Uveal Melanoma Reveals Two Molecular Classes and Predicts Metastatic Death
Onken et al.
Cancer Res. 2004;64:7205-7209.
ABSTRACT
| FULL TEXT
Distinct Mechanisms for Regulating the Tumor Suppressor and Antiapoptotic Functions of Rb
Ma et al.
J. Biol. Chem. 2003;278:19358-19366.
ABSTRACT
| FULL TEXT
|